BioSpace News Archive

Athenex, Inc. announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division, Orascovery, and Cell Therapy.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 for patients diagnosed with a microorganism infection.

Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of previously treated advanced colorectal carcinoma patients with KRASG12C mutation.